Is Biogen Stock a Buy Now?
Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. On July 6, the company announced that along with its longtime partner, Japan-based Esai, it had earned traditional approval for Leqembi, a therapy that targets patients with early AD.
It's an important achievement for Biogen, but oddly enough, the market responded with a shrug. Still, Leqembi could prove instrumental in turning Biogen's fortunes around. The company's stock has been highly volatile in recent years. But is it enough to make the company's stock a buy?
Source Fool.com
Biogen Inc. Stock
€177.82
1.010%
The stock is one of the favorites of our community with 42 Buy predictions and 1 Sell predictions.
With a target price of 200 € there is a slightly positive potential of 12.47% for Biogen Inc. compared to the current price of 177.82 €.
